Aratana nears approval for canine cancer vaccine
Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018.
The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 21, 2017 Category: American Health Authors: Elise Reuter Source Type: news
Aratana nears approval for canine cancer vaccine
Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018.
The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 21, 2017 Category: Biotechnology Authors: Elise Reuter Source Type: news
Aratana nears approval for canine cancer vaccine
Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018.
The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 21, 2017 Category: Health Management Authors: Elise Reuter Source Type: news
N.M. Paramedic Helps Young Cancer Patient With His 'Bucket List'
RIO RANCHO, N.M. (KRQE) –They met only once, but a strong bond ties a local paramedic to her former patient. Now, she’s hoping to help grant a big wish for a child battling cancer.
Paramedic Jennifer Saiz is a cancer survivor but her patient is still in the fight. She says his joyful spirit touched her so much, she wanted to help check off an item on his bucket list.
At the Dimas’ household, there are plenty of presents wrapped under the tree. But what’s on 10-year-old Elijah’s Christmas list can’t be tied with a bow.
“Visit the Pokémon center in Japan, get Nickelodeon slimed,” Elijah Dimas said.
It’...
Source: JEMS Administration and Leadership - December 13, 2017 Category: Emergency Medicine Authors: Francesca Washington, KRQE Tags: News Videos Administration and Leadership Source Type: news
PharmaMar presents positive results from a Phase II study of PM1183 in Ewing's sarcoma
(Pharmamar) PharmaMar (MSE:PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing ´ s sarcoma at the Connective Tissue Oncology Society ´ s (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news
HKBU Chinese medicine scholars develop HKBU Chinese medicine scholars develop
(Hong Kong Baptist University) Chinese Medicine scholars at Hong Kong Baptist University (HKBU) have succeeded in developing a novel targeted delivery system for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma (OS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2017 Category: International Medicine & Public Health Source Type: news
With three products out, Aratana chases its fourth: a canine cancer drug
With its third FDA-approved drug on the market, Aratana Therapeutics is hunting its next product, a canine cancer immunotherapy treatment.
The treatment, called AT-014, would be used to treat bone cancer, or osteosarcoma, in dogs. After a tumor is removed, a vaccine is used to prime the dog’s immune system to target any remaining cancer.
Aratana (Nasdaq: PETX) expects to obtain conditional licensure for the treatment from the U.S . Department of Agriculture before the end of 2017, which would… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 7, 2017 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news
Two classes of GGAA-microsatellites in a Ewing sarcoma context
(Nationwide Children's Hospital) In a study published in PLOS ONE, researchers describe two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. Ewing sarcoma is the second most common pediatric bone malignancy. It is initiated by chromosomal translocation t(11;22)(q24;q12), which creates the fusion protein and oncogenic driver EWS/FLI. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2017 Category: Cancer & Oncology Source Type: news
Just-in-time 3-D implants set to transform tumor surgery
(RMIT University) The project team will combine 3-D printing, robotic surgery and advanced manufacturing to create tailored implants for patients with bone cancer, dramatically improving patient and healthcare outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 29, 2017 Category: Cancer & Oncology Source Type: news
Three of the most deadly cancers get critical funding for research
Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer. Three scientists have received $1.3 million in critical funding from the Alliance for Cancer Gene Therapy (ACGT), the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news
Bone Cancer Survivor Selected for SpaceX Flight
Hayley Arceneaux will join billionaire Jared Isaacman, who wants to raise $200 million for St. Jude Children ' s Research Hospital (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pediatrics, Institutional, Source Type: news
Living With Cancer: Cancer Humor
Cracking up may be a better option than breaking down, or so three recent books by young people with cancer suggest. (Source: NYT Health)
Source: NYT Health - October 12, 2017 Category: Consumer Health News Authors: SUSAN GUBAR Tags: Breast Cancer Books and Literature Ewing's Sarcoma (Disease) Comedy and Humor Riggs, Nina (1977-2017) Harrison, Teva (1976- ) Ritvo, Max (1990-2016) Source Type: news
New drug hope for rare bone cancer patients
Patients with a rare bone cancer of the skull and spine - chordoma - could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust. In the largest genomics study of chordoma to date, published today in Nature Communications, scientists show that a group of chordoma patients have mutations in genes that are the target of existing drugs, known as PI3K inhibitors. (Source: World Pharma News)
Source: World Pharma News - October 12, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New drug hope for rare bone cancer patients
(Wellcome Trust Sanger Institute) Patients with a rare bone cancer of the skull and spine -- chordoma -- could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust. In the largest genomics study of chordoma to date, published today in Nature Communications, scientists show that a group of chordoma patients have mutations in genes that are the target of existing drugs, known as PI3K inhibitors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 12, 2017 Category: Cancer & Oncology Source Type: news
